MA37645B1 - Formulations stabilisées contenant des anticorps anti-dll4 - Google Patents
Formulations stabilisées contenant des anticorps anti-dll4Info
- Publication number
- MA37645B1 MA37645B1 MA37645A MA37645A MA37645B1 MA 37645 B1 MA37645 B1 MA 37645B1 MA 37645 A MA37645 A MA 37645A MA 37645 A MA37645 A MA 37645A MA 37645 B1 MA37645 B1 MA 37645B1
- Authority
- MA
- Morocco
- Prior art keywords
- formulations containing
- containing anti
- antibody
- dll4 antibodies
- stabilized formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 1
- 150000002016 disaccharides Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000008646 thermal stress Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
La présente invention concerne des formulations pharmaceutiques comprenant un anticorps qui se lie spécifiquement à un ligand humain delta-like 4 (dll4). Lesdites formulations peuvent contenir, outre un anticorps anti-dll4, un tampon de phosphate, un co-solvant organique, un disaccharide, et un sel. Les formulations pharmaceutiques selon la présente invention présentent un degré substantiel de stabilité d'anticorps après stockage pendant plusieurs mois et après avoir été soumises à une contrainte thermique et à d'autres contraintes physiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261653478P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/043516 WO2013181486A1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MA37645A2 MA37645A2 (fr) | 2016-08-31 |
| MA37645A3 MA37645A3 (fr) | 2017-07-31 |
| MA37645B1 true MA37645B1 (fr) | 2018-10-31 |
Family
ID=48670784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37645A MA37645B1 (fr) | 2012-05-31 | 2013-05-31 | Formulations stabilisées contenant des anticorps anti-dll4 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US9675692B2 (fr) |
| EP (1) | EP2854849B1 (fr) |
| JP (1) | JP6144758B2 (fr) |
| KR (1) | KR20150033615A (fr) |
| CN (1) | CN104349791A (fr) |
| AR (1) | AR092325A1 (fr) |
| AU (1) | AU2013267301B2 (fr) |
| BR (1) | BR112014028997A2 (fr) |
| CA (1) | CA2872275C (fr) |
| CL (1) | CL2014003237A1 (fr) |
| CO (1) | CO7151478A2 (fr) |
| DK (1) | DK2854849T3 (fr) |
| EA (1) | EA029779B1 (fr) |
| ES (1) | ES2668900T3 (fr) |
| HK (1) | HK1207305A1 (fr) |
| IL (1) | IL235468A0 (fr) |
| LT (1) | LT2854849T (fr) |
| MA (1) | MA37645B1 (fr) |
| MX (1) | MX357146B (fr) |
| NO (1) | NO2887943T3 (fr) |
| NZ (1) | NZ702288A (fr) |
| PH (1) | PH12014502429A1 (fr) |
| PL (1) | PL2854849T3 (fr) |
| PT (1) | PT2854849T (fr) |
| SG (1) | SG11201407171XA (fr) |
| SI (1) | SI2854849T1 (fr) |
| SM (1) | SMT201800216T1 (fr) |
| TW (1) | TWI609696B (fr) |
| UY (1) | UY34842A (fr) |
| WO (1) | WO2013181486A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE029661T2 (en) | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US20210379186A1 (en) * | 2018-04-16 | 2021-12-09 | Merck Patent Gmbh | Additives for protein formulations to improve thermal stability |
| CN120241997A (zh) | 2019-02-18 | 2025-07-04 | 伊莱利利公司 | 治疗性抗体制剂 |
| MX2022016218A (es) * | 2020-07-08 | 2023-03-31 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-ctla-4. |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| US5016784A (en) | 1990-02-15 | 1991-05-21 | Dexus Research Inc. | Applicator for highly reactive materials |
| AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| EP0852951A1 (fr) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Compositions pharmaceutiques stables, lyophilisées d'anticorps monoclonaux ou polyclonaux |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2635352C (fr) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Formulation stabilisee renfermant un anticorps |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| WO2005072772A1 (fr) | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Compositions pharmaceutiques |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2633574T3 (es) | 2005-03-25 | 2017-09-22 | Regeneron Pharmaceuticals, Inc. | Formulaciones de antagonistas de VEGF |
| BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| CA2654510C (fr) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Formulations antagonistes du vegf appropriees a une administration intravitreenne |
| CA2667466A1 (fr) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Administration intranasale de polypeptides et de proteines |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| HUE029661T2 (en) * | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| EP2501408B1 (fr) | 2009-11-20 | 2020-05-27 | Biocon Limited | Formulations d'anticorps |
| KR101853278B1 (ko) * | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | 치료학적 ｄｌｌ４ 결합 단백질 |
| NZ609557A (en) * | 2010-10-06 | 2014-12-24 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
-
2013
- 2013-05-29 AR ARP130101868A patent/AR092325A1/es unknown
- 2013-05-30 TW TW102119047A patent/TWI609696B/zh not_active IP Right Cessation
- 2013-05-31 CN CN201380028578.1A patent/CN104349791A/zh active Pending
- 2013-05-31 KR KR1020147035879A patent/KR20150033615A/ko not_active Withdrawn
- 2013-05-31 CA CA2872275A patent/CA2872275C/fr active Active
- 2013-05-31 WO PCT/US2013/043516 patent/WO2013181486A1/fr not_active Ceased
- 2013-05-31 BR BR112014028997A patent/BR112014028997A2/pt not_active IP Right Cessation
- 2013-05-31 NZ NZ702288A patent/NZ702288A/en not_active IP Right Cessation
- 2013-05-31 SG SG11201407171XA patent/SG11201407171XA/en unknown
- 2013-05-31 PL PL13730702T patent/PL2854849T3/pl unknown
- 2013-05-31 JP JP2015515218A patent/JP6144758B2/ja active Active
- 2013-05-31 ES ES13730702.1T patent/ES2668900T3/es active Active
- 2013-05-31 MX MX2014014363A patent/MX357146B/es active IP Right Grant
- 2013-05-31 EP EP13730702.1A patent/EP2854849B1/fr active Active
- 2013-05-31 LT LTEP13730702.1T patent/LT2854849T/lt unknown
- 2013-05-31 HK HK15108004.0A patent/HK1207305A1/xx unknown
- 2013-05-31 MA MA37645A patent/MA37645B1/fr unknown
- 2013-05-31 AU AU2013267301A patent/AU2013267301B2/en active Active
- 2013-05-31 US US13/906,479 patent/US9675692B2/en active Active
- 2013-05-31 SI SI201330979T patent/SI2854849T1/en unknown
- 2013-05-31 SM SM20180216T patent/SMT201800216T1/it unknown
- 2013-05-31 EA EA201492186A patent/EA029779B1/ru not_active IP Right Cessation
- 2013-05-31 PT PT137307021T patent/PT2854849T/pt unknown
- 2013-05-31 UY UY0001034842A patent/UY34842A/es unknown
- 2013-05-31 DK DK13730702.1T patent/DK2854849T3/en active
- 2013-08-23 NO NO13831626A patent/NO2887943T3/no unknown
-
2014
- 2014-10-29 PH PH12014502429A patent/PH12014502429A1/en unknown
- 2014-11-03 IL IL235468A patent/IL235468A0/en unknown
- 2014-11-27 CL CL2014003237A patent/CL2014003237A1/es unknown
- 2014-12-23 CO CO14281503A patent/CO7151478A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37645B1 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 | |
| MA35904B1 (fr) | Formulations stabilisées contenant des anticorps anti-ang2 | |
| Yewdell et al. | Original antigenic sin: how original? How sinful? | |
| MA33993B1 (fr) | Formulations stabilisées contenant des anticorps contre le récepteur de l'interleukine-6 (il-6r) | |
| MA35355B1 (fr) | Formulations stabilisées contenant des anticorps anti-pcsk9 | |
| AR130402A2 (es) | Formulaciones de anticuerpos anti-pdl1 | |
| MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
| TNSN07304A1 (en) | Combination of xolair with immunosuppressive agent | |
| JO3449B1 (ar) | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب | |
| MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
| JP2007520566A5 (fr) | ||
| EP3941945A4 (fr) | Anticorps dirigés contre l'antigène trophoblaste 2 de surface cellulaire (trop2) et conjugués anticorps-médicament les comprenant | |
| MA33023B1 (fr) | Formulation d'anticorps | |
| PH12013500672A1 (en) | Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies | |
| MA62173B1 (fr) | Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation | |
| EP2471814A4 (fr) | Anticorps monoclonal anti-vegf et composition pharmaceutique comprenant ledit anticorps | |
| IL194550A (en) | Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use | |
| FR18C1032I2 (fr) | Anticorps anti-fgf23 et composition pharmaceutique le comprenant | |
| EP2567982A4 (fr) | Anticorps dirigé contre l'antigène carcino-embryonnaire et ses utilisations | |
| IL214779A (en) | Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation | |
| MA34541B1 (fr) | Compositions d'anticorps et procédés d'utilisation | |
| PH12021552092A1 (en) | Stabilized formulations containing anti-il-33 antibodies | |
| Corral et al. | Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis | |
| EP3983446A4 (fr) | Anticorps anti-epcam conditionnellement actifs, fragments d'anticorps, leurs immunoconjugués et utilisations associées | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions |